LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Список акций・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Закрыт

СекторЗдравоохранение

2.47 -2.76

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

2.4699999999999998

Макс.

2.58

Ключевые показатели
By Trading Economics
Доход	4.1M -5.7M
Сотрудники	34
EBITDA	3.1M -6.8M

Рекомендации
By TipRanks
Рекомендации	Покупка
Прогноз на 12 месяцев	+687.4% upside

Дивиденды
By Acuity
Следующий отчет о доходах	16 июн. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-146M 243M
Предыдущая цена открытия	5.23
Предыдущая цена закрытия	2.47

Новостные настроения

By Acuity

50%

154 / 344 Рейтинг в Healthcare

Anavex Life Sciences Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

10 июн. 2026 г., 23:36 UTC

Correction to Oracle Reports Higher 4Q Profit Article

10 июн. 2026 г., 23:19 UTC

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 июн. 2026 г., 23:09 UTC

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 июн. 2026 г., 23:04 UTC

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 июн. 2026 г., 20:44 UTC

Caterpillar Raises Quarterly Dividend 8%

10 июн. 2026 г., 23:49 UTC

Elliott: Northern Star Should Take No Options Off The Table

10 июн. 2026 г., 23:48 UTC

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 июн. 2026 г., 23:48 UTC

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 июн. 2026 г., 23:47 UTC

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 июн. 2026 г., 23:47 UTC

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 июн. 2026 г., 23:46 UTC

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 июн. 2026 г., 23:38 UTC

Global Equities Roundup: Market Talk

10 июн. 2026 г., 23:38 UTC

Global Forex and Fixed Income Roundup: Market Talk

10 июн. 2026 г., 23:38 UTC

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 июн. 2026 г., 23:32 UTC

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 июн. 2026 г., 23:20 UTC

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 июн. 2026 г., 22:05 UTC

Correction to Bank of Canada Stays on Hold Market Talk

10 июн. 2026 г., 21:57 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 июн. 2026 г., 21:52 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 июн. 2026 г., 21:35 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 июн. 2026 г., 21:22 UTC

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 июн. 2026 г., 20:50 UTC

Tech, Media & Telecom Roundup: Market Talk

10 июн. 2026 г., 20:50 UTC

Financial Services Roundup: Market Talk

10 июн. 2026 г., 20:50 UTC

Basic Materials Roundup: Market Talk

10 июн. 2026 г., 20:50 UTC

Health Care Roundup: Market Talk

10 июн. 2026 г., 20:39 UTC

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 июн. 2026 г., 20:34 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 июн. 2026 г., 20:33 UTC

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 июн. 2026 г., 20:33 UTC

Global Equities Roundup: Market Talk

10 июн. 2026 г., 20:33 UTC

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Сравнение c конкурентами

Изменение цены

Anavex Life Sciences Corp Прогноз

Целевая цена

By TipRanks

687.4% рост

Прогноз на 12 месяцев

Средняя 20 USD 687.4%

Максимум 20 USD

Минимум 20 USD

Основано на мнении 2 аналитиков Wall Street, спрогнозировавших целевые цены для Anavex Life Sciences Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

2 ratings

Покупка

Удержание

Продажа

Основано на мнении 2 аналитиков, присваивавших рейтинги акциям Anavex Life Sciences Corp – Данные за последние 3 месяца.

Настроения

By Acuity

154 / 344Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.